Clinical Trials Logo

Clinical Trial Summary

In its report dated april 2014, World Health Organization confirms antibiotic resistance dissemination in all parts of the world, in hospitals and in community and worries about a possible comeback to a pre-antibiotic era during the 21st century. For the last 15 years, third-generation cephalosporins resistant enterobacteriaceae (3GCREB) prevalence is continuously increasing. Community 3GCREB prevalence has not been studied whereas several observations made in Reunion Island hospital suggest a diffusion in community. In this situation of world-wide and regional extension of bacterial resistance, the investigator offers to study bacterial resistance to antibiotic in Reunion Island community.


Clinical Trial Description

The investigator is focused on E. coli species exhibiting BLSE or metallo-betalactamases production that could be encountered du to the increasing level of migratory flow in Reunion Island.

Fecal sample collection will be used for further investigations on bacterial typology. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03226314
Study type Observational
Source Centre Hospitalier Universitaire de la Réunion
Contact
Status Active, not recruiting
Phase
Start date November 21, 2017
Completion date June 30, 2019

See also
  Status Clinical Trial Phase
Completed NCT02223338 - Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics N/A
Active, not recruiting NCT01208519 - SATURN 04 Nosocomial Acquisition Study N/A
Completed NCT03998865 - Bacterial Microbiota Characterization on Implant-supported PEEK and Titanium Provisional Abutments N/A
Not yet recruiting NCT03752476 - Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria
Completed NCT05939479 - Antistaphylococcal Betalactam and Emergence of Resistance
Completed NCT02641015 - Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING) N/A
Completed NCT01878643 - Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit Phase 0